REARDON ANDREW (CLO & Secretary) sold 12.0% of their position (5K shares) of LIGAND PHARMACEUTICALS INC on the open market
Open‑market sale worth $1.43M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 5 sales
Filed: 9/8/2026ACC: 0002001011-26-000137
Officer· CLO & Secretary
Since Mar 2026
-5K
Net shares
Net seller
$1.43M
Total sold
5
Open market trades
0B · 5S
5
Total transactions
5K disposed
Non-Derivative Transactions5
Common Stock
Direct
Shares
−300.00
Price / share
$283.99
Trade value
$85.20K
% of position
0.7%
9/3/2026
41.51K→41.21K
Common Stock
Direct
Shares
−1.80K
Price / share
$285.17
Trade value
$513.30K
% of position
4.4%
9/3/2026
41.21K→39.41K
Common Stock
Direct
Shares
−2.12K
Price / share
$286.36
Trade value
$605.65K
% of position
5.4%
9/3/2026
39.41K→37.30K
Common Stock
Direct
Shares
−385.00
Price / share
$287.53
Trade value
$110.70K
% of position
1.0%
9/3/2026
37.30K→36.91K
Common Stock
Direct
Shares
−400.00
Price / share
$288.98
Trade value
$115.59K
% of position
1.1%
9/3/2026
36.91K→36.51K
Total
Net shares
−5K
Net value
-$1.43M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/3/2026 | S · Sale | −300.00 | $283.99 | $85.20K | 0.7% | 41.51K | 41.21K |
| Common Stock Direct | 9/3/2026 | S · Sale | −1.80K | $285.17 | $513.30K | 4.4% | 41.21K | 39.41K |
| Common Stock Direct | 9/3/2026 | S · Sale | −2.12K | $286.36 | $605.65K | 5.4% | 39.41K | 37.30K |
| Common Stock Direct | 9/3/2026 | S · Sale | −385.00 | $287.53 | $110.70K | 1.0% | 37.30K | 36.91K |
| Common Stock Direct | 9/3/2026 | S · Sale | −400.00 | $288.98 | $115.59K | 1.1% | 36.91K | 36.51K |
| Total | −5K | -$1.43M | ||||||
Derivative Transactions0
No derivative transactions reported